A Prospective Single Arm, Open-label, International, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder With Ritonavir (RTV) With Optimal Background Therapy, in HIV Infected Pediatric Patients Greater Than or Equal to 3 Months to Less Than 6 Years (Pediatric Atazanavir International Clinical Evaluation: the PRINCE I Study)

Trial Profile

A Prospective Single Arm, Open-label, International, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder With Ritonavir (RTV) With Optimal Background Therapy, in HIV Infected Pediatric Patients Greater Than or Equal to 3 Months to Less Than 6 Years (Pediatric Atazanavir International Clinical Evaluation: the PRINCE I Study)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Atazanavir (Primary) ; Ritonavir
  • Indications HIV-1 infections
  • Focus Adverse reactions; Registrational
  • Acronyms PRINCE I
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 02 Feb 2017 Planned End Date changed from 1 Mar 2017 to 1 Sep 2017.
    • 30 Mar 2012 Planned end date changed from 1 Oct 2016 to 1 Mar 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top